Schedule 13D ownership disclosure

AXOVANT SCIENCES LTD

Security class unavailable · CUSIP: G0750W104

Event date: 2019-03-18

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
105,952,381
Percent of class
58.1500%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-19-016025
Form type
SC 13D
Filer
Sio Gene Therapies Inc.
CIK
CIK 1636050
Filed
Mar 19, 2019
Reporting period
Mar 18, 2019
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub